BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31488714)

  • 21. Neurokinin-1 receptor antagonism improves postoperative neurocognitive disorder in mice.
    Li Z; Luo T; Ning X; Xiong C; Wu A
    Neurosci Lett; 2018 Nov; 687():189-195. PubMed ID: 30273701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
    Muñoz M; González-Ortega A; Coveñas R
    Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation.
    Lai JP; Ho WZ; Kilpatrick LE; Wang X; Tuluc F; Korchak HM; Douglas SD
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7771-6. PubMed ID: 16675550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Varicella Zoster Virus Induces Nuclear Translocation of the Neurokinin-1 Receptor, Promoting Lamellipodia Formation and Viral Spread in Spinal Astrocytes.
    Bubak AN; Como CN; Blackmon AM; Frietze S; Mescher T; Jones D; Cohrs RJ; Paucek P; Baird NL; Nagel MA
    J Infect Dis; 2018 Sep; 218(8):1324-1335. PubMed ID: 29788447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes.
    Guo CJ; Douglas SD; Gao Z; Wolf BA; Grinspan J; Lai JP; Riedel E; Ho WZ
    Glia; 2004 Nov; 48(3):259-66. PubMed ID: 15390113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
    Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
    Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic epithelial cells.
    Koon HW; Zhao D; Zhan Y; Rhee SH; Moyer MP; Pothoulakis C
    J Immunol; 2006 Apr; 176(8):5050-9. PubMed ID: 16585602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor.
    Schwartz L; Spitsin SV; Meshki J; Tuluc F; Douglas SD; Wolfe JH
    J Neurovirol; 2013 Jun; 19(3):219-27. PubMed ID: 23765222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme.
    Afshari AR; Motamed-Sanaye A; Sabri H; Soltani A; Karkon-Shayan S; Radvar S; Javid H; Mollazadeh H; Sathyapalan T; Sahebkar A
    Curr Med Chem; 2021; 28(24):4877-4892. PubMed ID: 33441062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The N-terminal domain of substance P is required for complete homologous desensitization but not phosphorylation of the rat neurokinin-1 receptor.
    Vigna SR
    Neuropeptides; 2001 Feb; 35(1):24-31. PubMed ID: 11346307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
    Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
    Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced Neurokinin-1 Receptor Expression Is Associated with Human Dental Pulp Inflammation and Pain Severity.
    Mehboob R; Hassan S; Gilani SA; Hassan A; Tanvir I; Waseem H; Hanif A
    Biomed Res Int; 2021; 2021():5593520. PubMed ID: 34041298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
    Nizam E; Erin N
    Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of substance P and its receptor neurokinin-1 in psoriasis and their relation to chronic stress and pruritus.
    Remröd C; Lonne-Rahm S; Nordlind K
    Arch Dermatol Res; 2007 May; 299(2):85-91. PubMed ID: 17370082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The progesterone derivative dydrogesterone down-regulates neurokinin 1 receptor expression on lymphocytes, induces a Th2 skew and exerts hypoalgesic effects in mice.
    Orsal AS; Blois S; Labuz D; Peters EM; Schaefer M; Arck PC
    J Mol Med (Berl); 2006 Feb; 84(2):159-67. PubMed ID: 16389545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substance P modulates colitis-associated fibrosis.
    Koon HW; Shih D; Karagiannides I; Zhao D; Fazelbhoy Z; Hing T; Xu H; Lu B; Gerard N; Pothoulakis C
    Am J Pathol; 2010 Nov; 177(5):2300-9. PubMed ID: 20889569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involvement of substance P and the NK-1 receptor in pancreatic cancer.
    Muñoz M; Coveñas R
    World J Gastroenterol; 2014 Mar; 20(9):2321-34. PubMed ID: 24605029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alcohol dependence potentiates substance P/neurokinin-1 receptor signaling in the rat central nucleus of amygdala.
    Khom S; Steinkellner T; Hnasko TS; Roberto M
    Sci Adv; 2020 Mar; 6(12):eaaz1050. PubMed ID: 32206720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the Neurokinin-1 Receptor in the Promotion of Corneal Epithelial Wound Healing by the Peptides FGLM-NH2 and SSSR in Neurotrophic Keratopathy.
    Yanai R; Nishida T; Hatano M; Uchi SH; Yamada N; Kimura K
    Invest Ophthalmol Vis Sci; 2020 Jul; 61(8):29. PubMed ID: 32697304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.